Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Current opinion in investigational drugs

• Publication date

  2006-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 16784024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Orally active purine-based inhibitors of the heat shock protein 90.

  2006cited by this paper
• Targeting chaperones in transformed systems – a focus on Hsp90 and cancer

  2006cited by this paper
• Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications.

  2006cited by this paper
• Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles.

  2005cited by this paper
• Hsp90 inhibitors identified from a library of novobiocin analogues.

  2005cited by this paper
• The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.

  2005cited by this paper
• Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers

  2005cited by this paper
• Regulation of the Dynamics of hsp90 Action on the Glucocorticoid Receptor by Acetylation/Deacetylation of the Chaperone*

  2005cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

  2005cited by this paper
• Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase.

  2005cited by this paper
• Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models

  2005cited by this paper
• Design, synthesis, and biological evaluation of HSP90 inhibitors based on conformational analysis of radicicol and its analogues.

  2005cited by this paper
• Radester, a novel inhibitor of the Hsp90 protein folding machinery.

  2005cited by this paper
• Modulating molecular chaperone Hsp90 functions through reversible acetylation.

  2005cited by this paper
• HSP90 and the chaperoning of cancer

  2005cited by this paper
• Rational design of shepherdin, a novel anticancer agent.

  2005cited by this paper
• Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

  2005cited by this paper
• Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.

  2005cited by this paper
• Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design.

  2005cited by this paper
• Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

  2005cited by this paper
• S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities.

  2005cited by this paper
• Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity

  2004cited by this paper
• Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.

  2004cited by this paper
• Hsp70 and Hsp90--a relay team for protein folding.

  2004cited by this paper
• Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.

  2004cited by this paper
• Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures.

  2004cited by this paper
• Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin.

  2003cited by this paper
• Development of purine-scaffold small molecule inhibitors of Hsp90.

  2003cited by this paper
• Development of radicicol analogues.

  2003cited by this paper
• Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors

  2003cited by this paper
• Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol.

  2003cited by this paper
• Natural product origins of Hsp90 inhibitors.

  2003cited by this paper
• Clinical development of 17-allylamino, 17-demethoxygeldanamycin.

  2003cited by this paper
• 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

  2002cited by this paper
• Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.

  2002cited by this paper
• A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells.

  2001cited by this paper
• Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.

  2000cited by this paper
• Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.

  2000cited by this paper
• The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin

  1998cited by this paper
• Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent.

  1997cited by this paper
• Polyubiquitination and Proteasomal Degradation of the p185c-erbB-2 Receptor Protein-tyrosine Kinase Induced by Geldanamycin*

  1996cited by this paper
• Heat-shock protein hsp90 governs the activity of pp60v-src kinase.

  1993cited by this paper
• Two cellular proteins that immunoprecipitate with the transforming protein of Rous sarcoma virus.

  1981cited by this paper

• Antioxidant and Antimicrobial Potential, BSA and DNA Binding Properties of Some 3-Hydroxy-3-Pyrrolin-2-Ones Bearing Thenoyl Fragment.

  2022cites this paper
• Synthesis, characterization, antitumor potential, BSA and DNA binding properties, and molecular docking study of some novel 3-hydroxy-3-pyrrolin-2-ones.

  2021cites this paper
• Selection the Drug Efficacy of Oroidin Derivatives as Hsp90 Inhibitors by Computer Aided Drug Design Method

  2020influential citation
• 2,4-Diketo esters: Crucial intermediates for drug discovery.

  2020cites this paper
• Deiminated proteins and extracellular vesicles - Novel serum biomarkers in whales and orca.

  2020cites this paper
• Screening Technique for Heat Shock Protein 90 Inhibitors from Natural Products

  2019cites this paper
• Inhibition of Heat Shock Protein 90 as a Novel Platform for the Treatment of Cancer.

  2019cites this paper
• Deiminated proteins in extracellular vesicles and serum of llama (Lama glama)—Novel insights into camelid immunity

  2019cites this paper
• BIIB021: A novel inhibitor to heat shock protein 90–addicted oncology

  2017cites this paper
• Heat shock proteins and kidney disease: perspectives of HSP therapy

  2017cites this paper
• Heat shock protein 90 is involved in the regulation of HMGA2-driven growth and epithelial-to-mesenchymal transition of colorectal cancer cells

  2016cites this paper
• Quantitative proteomic analysis and comparison of two bone marrow stromal cell lines using the SILAC method.

  2016cites this paper
• The ubiquitin proteasome system as a potential therapeutic target for treatment of neurodegenerative diseases.

  2015cites this paper
• Triple Negative Breast Cancer: Molecular Classification, Prognostic Markers and Targeted Therapies

  2015cites this paper
• Selection and Characterization of Single Chain Antibody Fragments Specific for Hsp90 as a Potential Cancer Targeting Molecule

  2015cites this paper
• Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression

  2015cites this paper
• Heat shock protein 90 inhibitors repurposed against Entamoeba histolytica

  2015cites this paper
• Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).

  2014cites this paper
• Chronic Treatment with Novel Small Molecule Hsp90 Inhibitors Rescues Striatal Dopamine Levels but Not α-Synuclein-Induced Neuronal Cell Loss

  2014cites this paper
• Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.

  2014cites this paper
• Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance

  2013influential citation
• F508del-CFTR rescue: a matter of cell stress response.

  2013cites this paper
• PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α

  2013cites this paper
• Current concepts in clinical radiation oncology

  2013cites this paper
• Cancer Therapy : Preclinical A Purine Scaffold HSP 90 Inhibitor BIIB 021 Has Selective Activity against KSHV-Associated Primary Effusion Lymphoma and Blocks vFLIP K 13-Induced NFk B

  2013cites this paper
• Homology modeling, ligand docking and in silico mutagenesis of neurospora Hsp80 (90): insight into intrinsic ATPase activity.

  2013cites this paper
• The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer

  2013cites this paper
• Virtual Screening and Molecular Descriptor Analysis on Dietary Phytochemicals Against Heat Shock Protein 90 Enzyme

  2013cites this paper
• Hsp90: still a viable target in prostate cancer.

  2013cites this paper
• Hsp90, an unlikely ally in the war on cancer

  2013cites this paper
• A Purine Scaffold HSP90 Inhibitor BIIB021 Has Selective Activity against KSHV-Associated Primary Effusion Lymphoma and Blocks vFLIP K13-Induced NF-κB

  2013cites this paper
• Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors

  2013cites this paper
• A Purine Analog Synergizes with Chloroquine (CQ) by Targeting Plasmodium falciparum Hsp90 (PfHsp90)

  2013cites this paper
• Award Number: W81XWH-11-1-0150 TITLE: Protection by Purines in Toxin Models of Parkinson's Disease PRINCIPAL INVESTIGATOR:

  2012cites this paper
• Estradiol receptors in breast cancer cells: associated co-factors as targets for new therapeutic approaches.

  2012cites this paper
• High-throughput screening identifies small molecule inhibitors of molecular chaperones.

  2012cites this paper
• INTEGRATION OF HSP90 INHIBITION IN COMBINATIONAL IMMUNOTHERAPIES TARGETING RECEPTOR TYROSINE KINASE EPHA2

  2012cites this paper
• In vitro Studie zur Effektivität von Hsp90-Inhibitoren bei der Therapie des Ösophaguskarzinoms

  2012cites this paper
• Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors

  2011influential citation
• A Novel HSP90 Inhibitor Delays Castrate-Resistant Prostate Cancer without Altering Serum PSA Levels and Inhibits Osteoclastogenesis

  2011cites this paper
• Inhibitors of the heat shock protein 90: from cancer clinical trials to neurodegenerative diseases

  2011cites this paper
• A systematic protocol for the characterization of Hsp90 modulators.

  2011cites this paper
• Heat shock proteins: a potential anticancer target.

  2011cites this paper
• Some sulfonamide drugs inhibit ATPase activity of heat shock protein 90: investigation by docking simulation and experimental validation

  2011cites this paper
• Nature as Source of Medicines; Novel Drugs from Nature; Screening for Antitumor Activity

  2010cites this paper
• STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.

  2010cites this paper
• 小细胞肺癌的的分子发病机制

  2010cites this paper
• Rôle des protéines de choc thermique HSP90 et HSP70 dans la différenciation macrophagique

  2010cites this paper
• Targeting the Hsp90 chaperone: synthesis of novel resorcylic acid macrolactone inhibitors of Hsp90.

  2010cites this paper
• Histone Deacetylase Inhibitors: The Epigenetic Therapeutics That Repress Hypoxia-Inducible Factors

  2010cites this paper
• The anti-myeloma activity of a novel purine scaffold HSP 90 inhibitor PUH 71 is via inhibition of both HSP 90 A and HSP 90 B 1

  2010cites this paper
• The molecular pathogenesis of small cell lung cancer

  2010cites this paper
• Anti-malaria drug blocks proteotoxic stress response:

  2010cites this paper
• The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1

  2010cites this paper
• HSP90 and its inhibitors.

  2010cites this paper
• Update on Hsp90 inhibitors in clinical trial.

  2009cites this paper
• 17 AAG for HSP90 inhibition in cancer--from bench to bedside.

  2009cites this paper
• Solution-phase parallel synthesis of Hsp90 inhibitors.

  2009cites this paper
• HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.

  2009cites this paper
• Microwave-assisted one step synthesis of 8-arylmethyl-9H-purin-6-amines.

  2009cites this paper
• Synthesis of pochoxime prodrugs as potent HSP90 inhibitors.

  2009cites this paper
• Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.

  2009cites this paper
• Inhibition of HSP90 with Pochoximes: SAR and Structure‐Based Insights

  2009cites this paper
• Structural and computational biology of the molecular chaperone Hsp90: from understanding molecular mechanisms to computer-based inhibitor design.

  2009cites this paper
• Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.

  2009cites this paper
• Anti-malaria drug blocks proteotoxic stress response: Anti-cancer implications

  2009cites this paper
• ESTUDIO DE LA FORMACIÓN Y DEGRADACIÓN DE UN AGRESOMA DE ACTINA El director El autor

  2009cites this paper
• Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.

  2009cites this paper
• Impact of natural products on developing new anti-cancer agents.

  2009cites this paper
• Naturally diverse: highlights in versatile synthetic methods enabling target- and diversity-oriented synthesis.

  2009cites this paper
• Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design.

  2009cites this paper
• Discovery and development of purine-scaffold Hsp90 inhibitors

  2008cites this paper
• NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

  2008cites this paper
• Dynamics of an F-actin aggresome generated by the actin-stabilizing toxin jasplakinolide

  2008cites this paper
• Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.

  2008cites this paper
• Heat shock proteins: essential proteins for apoptosis regulation

  2008cites this paper
• Dynamics of conserved waters in human Hsp90: implications for drug design

  2008cites this paper
• Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor.

  2008cites this paper
• Development and application of Hsp90 inhibitors.

  2008cites this paper
• Medicinal chemistry of Hsp90 inhibitors.

  2008cites this paper
• Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90).

  2008cites this paper
• The Hsp90 molecular chaperone: an open and shut case for treatment.

  2008cites this paper
• Targeting Hsp90: small-molecule inhibitors and their clinical development.

  2008cites this paper
• Neuroprotective Features Of Hsp90 Inhibitors Exhibiting Anti-Inflammatory Actions: Implications For Multiple Sclerosis

  2008cites this paper
• HSP90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways

  2008cites this paper
• Heat shock protein-90 directed therapeutics and target validation

  2008cites this paper
• Implicación de los filamentos de actina en la arquitectura, homeostasis y tráfico de salida del aparato de Golgi y estudio de la formación y degradación de un agresoma de actina

  2008cites this paper
• Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies

  2007cites this paper
• 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.

  2007cites this paper
• Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

  2007cites this paper
• Implications of Heat Shock Proteins in Carcinogenesis and Cancer Progression

  2007cites this paper
• Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer.

  2007cites this paper
• DRUGGING THE HSP90 MOLECULAR CHAPERONE MACHINE FOR CANCER TREATMENT

  2007cites this paper
• Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.

  2007cites this paper
• Targeting Hsp90: The Cancer Super-Chaperone

  2007cites this paper
• Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer.

  2007cites this paper
• High-Throughput Screening Fluorescence Polarization Assay for Tumor-Specific Hsp90

  2007cites this paper
• Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis.

  2007cites this paper
• Targeting of multiple signalling pathways 90 molecular chaperone inhibitors

  2007cites this paper
• Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

  2006cites this paper